CEL-SCI (CVM) said late Wednesday it priced an offering of 2 million shares at $2.50 apiece, targeting gross proceeds of $5 million.
The company granted underwriters a 45-day option to purchase up to 190,000 additional shares to cover over-allotments.
The firm plans to use net proceeds to fund the development of its Multikine investigational therapy, for general corporate purposes, and as working capital.
The offering is due to close on Friday.
CEL-SCI's shares were down 26% in after-hours activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.